Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: A multicenter series

Neurocritical Care

Volumn 15, Issue 1, 2011, Pages 85-95

  Walsh, Ryan D ^a   Barrett, Kevin M ^a   Aguilar, Maria I ^b   Lanzino, Giuseppe ^c   Hanel, Ricardo A ^a   Miller, David A ^a   Chong, Brian W ^b   Freeman, W David ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

Abciximab; Aneurysm coiling; Glycoprotein IIb IIIa (GP IIb IIIa) receptor inhibitor; Intracranial hemorrhage; Mortality; Neuroendovascular; Neurointervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN;

ADULT; AGED; ANEURYSM SURGERY; ANGIOPLASTY; ARTICLE; BLOOD CLOTTING TIME; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBRAL REVASCULARIZATION; COMORBIDITY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; ENDOVASCULAR SURGERY; ENTERAL DRUG ADMINISTRATION; FEMALE; GLASGOW OUTCOME SCALE; HOSPITAL DISCHARGE; HUMAN; INTRAPARENCHYMAL HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROENDOVASCULAR PROCEDURE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; STENT; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 80052608319     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-010-9338-1     Document Type: Article

References (26)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-61.
2. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998; 97:1680-8. (Pubitemid 28211416)
3. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90: 1757-64. (Pubitemid 24320922)
4. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet. 2001;357:1905-14. (Pubitemid 32568330)
5. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
6. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet. 1997; 349:1429-35.
7. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-96.
8. Levy EI, Mehta R, Gupta R, et al. Self-expanding stents for recanalization of acute cerebrovascular occlusions. AJNR Am J Neuroradiol. 2007;28:816-22. (Pubitemid 46776054)
9. Qureshi AI, Saad M, Zaidat OO, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002;33:1916-9. (Pubitemid 34761085)
10. Qureshi AI, Suri MF, Khan J, Fessler RD, Guterman LR, Hopkins LN. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: Preliminary experience. Neurosurgery. 2000; 46:1316-25. (Pubitemid 32037664)
11. Velat GJ, Burry MV, Eskioglu E, Dettorre RR, Firment CS, Mericle RA. The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures. Surg Neurol. 2006;65:352-9.
12. Park JH, Kim JE, Sheen SH, et al. Intraarterial abciximab for treatment of thromboembolism during coil embolization of intracranial aneurysms: Outcome and fatal hemorrhagic complications. J Neurosurg. 2008;108:450-7.
13. Chan AW, Yadav JS, Bhatt DL, et al. Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting. Am J Cardiol. 2005;95:791-5. (Pubitemid 40332666)
14. Jones RG, Davagnanam I, Colley S, West RJ, Yates DA. Abciximab for treatment of thromboembolic complications during endovascular coiling of intracranial aneurysms. AJNR Am J Neuroradiol. 2008;29:1925-9.
15. Aviv RI, O'Neill R, Patel MC, Colquhoun IR. Abciximab in patients with ruptured intracranial aneurysms. AJNR Am J Neuroradiol. 2005;26:1744-50. (Pubitemid 43853674)
16. Gralla J, Rennie AT, Corkill RA, et al. Abciximab for thrombolysis during intracranial aneurysm coiling. Neuroradiology. 2008;50:1041-7.
17. Song JK, Niimi Y, Fernandez PM, et al. Thrombus formation during intracranial aneurysm coil placement: Treatment with intra-arterial abciximab. AJNR Am J Neuroradiol. 2004;25: 1147-53. (Pubitemid 39095158)
18. Mounayer C, Piotin M, Baldi S, Spelle L, Moret J. Intraarterial administration of Abciximab for thromboembolic events occurring during aneurysm coil placement. AJNR Am J Neuroradiol. 2003;24:2039-43. (Pubitemid 37444856)
19. Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
20. Vahdat B, Canavy I, Fourcade L, et al. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv. 2000;49:177-80. (Pubitemid 30075543)
21. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-4.
22. Coller BS. A new murine monoclonal antibody reports an activation- dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-8. (Pubitemid 15240423)
23. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest. 1996; 98:863-74. (Pubitemid 26349192)
24. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000;139:S38-45. (Pubitemid 30091780)
25. Akkerhuis KM, Deckers JW, Lincoff AM, et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA. 2001;286:78-82. (Pubitemid 32606335)
26. Ries T, Siemonsen S, Grzyska U, Zeumer H, Fiehler J. Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: Single center experience in 42 cases and review of the literature. Stroke. 2009;40:1750-7.